Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Core Viewpoint - Ironwood Pharmaceuticals, Inc. has announced its financial guidance for the full year 2026, highlighting significant progress in maximizing LINZESS and maintaining sustained profits and cash flows to strengthen its financial position and comply with debt covenants [1] Financial Performance - In 2025, the company made substantial advancements in its operations, particularly with LINZESS, which contributed to sustained profits and cash flows [1] - The focus on financial stability is aimed at ensuring compliance with debt covenants in the upcoming periods [1]